In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 3, 2011, Pages 637-646

  Cheng, Hua ^a,b   An, She Juan ^a   Zhang, Xu Chao ^a   Dong, Song ^a   Zhang, Yi Fang ^a   Chen, Zhi Hong ^a   Chen, Hua Jun ^a   Guo, Ai Lin ^a   Lin, Qiu Xiong ^a   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor tyrosine kinase; Lung cancer

Indexed keywords

GEFITINIB; PACLITAXEL; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG POTENTIATION; EFGR ONCOGENE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; INTERPHASE; LUNG NON SMALL CELL CANCER; MITOSIS; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; CELL CYCLE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; LUNG TUMOR; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; PACLITAXEL; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 79953795924     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1347-4     Document Type: Article

References (50)

1. A Jemal MJ Thun LA Ries, et al. 2008 Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control J Natl Cancer Inst 100 23 1672 1694 10.1093/jnci/djn389 19033571
2. MA Socinski R Crowell TE Hensing, et al. 2007 Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edn) Chest 132 3 Suppl 277S 289S 10.1378/chest.07-1381 17873174
3. E Felip RA Stahel N Pavlidis 2005 ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC) Ann Oncol 16 Suppl 1 i28 i29 10.1093/annonc/mdi821 15888743 (Pubitemid 40872978)
4. JH Schiller D Harrington CP Belani, et al. 2002 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2 92 98 1:CAS:528:DC%2BD38Xkt1OlsQ%3D%3D 10.1056/NEJMoa011954 11784875 (Pubitemid 34438899)
5. EF Smit JP van Meerbeeck P Lianes, et al. 2003 Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975 J Clin Oncol 21 21 3909 3917 1:CAS:528:DC%2BD2cXpsVajsLY%3D 10.1200/JCO.2003.03.195 14581415 (Pubitemid 46606203)
6. FA Shepherd J Dancey R Ramlau, et al. 2000 Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 10 2095 2103 1:CAS:528:DC%2BD3cXktVyjsLc%3D 10811675 (Pubitemid 30324363)
7. N Hanna FA Shepherd FV Fossella, et al. 2004 Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 9 1589 1597 1:CAS:528:DC%2BD2cXpsVWmurk%3D 10.1200/JCO.2004.08.163 15117980 (Pubitemid 41079796)
8. ES Kim V Hirsh T Mok, et al. 2008 Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 9652 1809 1818 1:CAS:528:DC%2BD1cXhsVWhtbjM 10.1016/S0140-6736(08)61758-4 19027483
9. TJ Lynch DW Bell R Sordella, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 21 2129 2139 1:CAS:528: DC%2BD2cXktF2js7c%3D 10.1056/NEJMoa040938 15118073 (Pubitemid 38637993)
10. JG Paez PA Janne JC Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 5676 1497 1500 1:CAS:528:DC%2BD2cXksVGmsbs%3D 10.1126/science.1099314 15118125 (Pubitemid 38720929)
11. TS Mok YL Wu S Thongprasert, et al. 2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 10 947 957 1:CAS:528:DC%2BD1MXhtVygsbfK 10.1056/NEJMoa0810699 19692680
12. YL Wu WZ Zhong LY Li, et al. 2007 Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China J Thorac Oncol 2 5 430 439 10.1097/01.JTO.0000268677.87496.4c 17473659 (Pubitemid 47181698)
13. PB Schiff J Fant SB Horwitz 1979 Promotion of microtubule assembly in vitro by taxol Nature 277 5698 665 667 1:CAS:528:DyaE1MXkvVCitrY%3D 10.1038/277665a0 423966 (Pubitemid 9114288)
14. F Ciardiello R Caputo R Bianco, et al. 2000 Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor Clin Cancer Res 6 5 2053 2063 1:CAS:528:DC%2BD3cXktVWitrs%3D 10815932 (Pubitemid 30305105)
15. FM Sirotnak MF Zakowski VA Miller HI Scher MG Kris 2000 Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin Cancer Res 6 12 4885 4892 1:CAS:528:DC%2BD3MXotlektQ%3D%3D 11156248 (Pubitemid 32110433)
16. G Giaccone RS Herbst C Manegold, et al. 2004 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 5 777 784 1:CAS:528:DC%2BD2cXpsVKjur4%3D 10.1200/JCO.2004.08.001 14990632 (Pubitemid 41103588)
17. RS Herbst G Giaccone JH Schiller, et al. 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 5 785 794 1:CAS:528:DC%2BD2cXpsVKjur0%3D 10.1200/JCO.2004.07.215 14990633 (Pubitemid 41103589)
18. T Mosmann 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 1-2 55 63 1:STN:280:DyaL2c%2FovFSmtw%3D%3D 10.1016/0022-1759(83)90303-4 6606682 (Pubitemid 14203433)
19. J Carmichael WG DeGraff AF Gazdar JD Minna JB Mitchell 1987 Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing Cancer Res 47 4 936 942 1:CAS:528:DyaL2sXhsVyrtb0%3D 3802100 (Pubitemid 17027905)
20. J Baselga D Rischin M Ranson, et al. 2002 Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types J Clin Oncol 20 21 4292 4302 1:CAS:528: DC%2BD38Xpt1CjtLo%3D 10.1200/JCO.2002.03.100 12409327 (Pubitemid 35266289)
21. TC Chou 2006 Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 3 621 681 1:CAS:528:DC%2BD28XhtVOhtLfL 10.1124/pr.58.3.10 16968952 (Pubitemid 44403686)
22. K Torres SB Horwitz 1998 Mechanisms of Taxol-induced cell death are concentration dependent Cancer Res 58 16 3620 3626 1:CAS:528:DyaK1cXlsFajt7o%3D 9721870 (Pubitemid 28376560)
23. RA Tobey EC Anderson DF Petersen 1967 Properties of mitotic cells prepared by mechanically shaking monolayer cultures of Chinese hamster cells J Cell Physiol 70 1 63 68 1:STN:280:DyaF1c3gt1Wiug%3D%3D 10.1002/jcp.1040700109 4869346
24. JG Chen CP Yang M Cammer SB Horwitz 2003 Gene expression and mitotic exit induced by microtubule-stabilizing drugs Cancer Res 63 22 7891 7899 1:CAS:528:DC%2BD3sXptFOlt7k%3D 14633718 (Pubitemid 37466724)
25. KE Gascoigne SS Taylor 2008 Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs Cancer Cell 14 2 111 122 1:CAS:528:DC%2BD1cXhtVSrtrjN 10.1016/j.ccr.2008.07.002 18656424
26. CL Rieder H Maiato 2004 Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint Dev Cell 7 5 637 651 1:CAS:528:DC%2BD2cXhtVWgsLnK 10.1016/j.devcel.2004.09.002 15525526 (Pubitemid 39462685)
27. KE Gascoigne SS Taylor 2009 How do anti-mitotic drugs kill cancer cells? J Cell Sci 122 Pt 15 2579 2585 1:CAS:528:DC%2BD1MXhtVGhsL7F 10.1242/jcs.039719 19625502
28. DA Brito CL Rieder 2006 Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint Curr Biol 16 12 1194 1200 1:CAS:528:DC%2BD28XlvF2jtrk%3D 10.1016/j.cub.2006.04.043 16782009 (Pubitemid 43867292)
29. MA Jordan K Wendell S Gardiner WB Derry H Copp L Wilson 1996 Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death Cancer Res 56 4 816 825 1:CAS:528:DyaK28XhtVClsbo%3D 8631019 (Pubitemid 26055472)
30. PR Andreassen SN Martineau RL Margolis 1996 Chemical induction of mitotic checkpoint override in mammalian cells results in aneuploidy following a transient tetraploid state Mutat Res 372 2 181 194 1:CAS:528:DyaK28Xnt1Oitbo%3D 9015137 (Pubitemid 27039398)
31. HC Huang J Shi JD Orth TJ Mitchison 2009 Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly Cancer Cell 16 4 347 358 1:CAS:528:DC%2BD1MXhsVCjtrnN 10.1016/j.ccr.2009.08.020 19800579
32. R Sordella DW Bell DA Haber J Settleman 2004 Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 5687 1163 1167 1:CAS:528:DC%2BD2cXmslCmur8%3D 10.1126/science.1101637 15284455 (Pubitemid 39100331)
33. S Tracy T Mukohara M Hansen M Meyerson BE Johnson PA Janne 2004 Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255 Cancer Res 64 20 7241 7244 1:CAS:528:DC%2BD2cXosFynt7w%3D 10.1158/0008-5472.CAN- 04-1905 15492241 (Pubitemid 39372059)
34. GC Chang SL Hsu JR Tsai, et al. 2004 Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells Biochem Pharmacol 68 7 1453 1464 1:CAS:528:DC%2BD2cXntlemt7Y%3D 10.1016/j.bcp.2004.06.006 15345335 (Pubitemid 39179402)
35. JD Moyer EG Barbacci KK Iwata, et al. 1997 Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 57 21 4838 4848 1:CAS:528:DyaK2sXnt12nsr4%3D 9354447 (Pubitemid 27468992)
36. MV Blagosklonny T Schulte P Nguyen J Trepel LM Neckers 1996 Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway Cancer Res 56 8 1851 1854 1:CAS:528:DyaK28Xitlyks7Y%3D 8620503
37. MV Blagosklonny P Giannakakou WS El-Deiry, et al. 1997 Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death Cancer Res 57 1 130 135 1:CAS:528:DyaK2sXktVagsg%3D%3D 8988053 (Pubitemid 27020341)
38. JP MacKeigan DJ Taxman D Hunter HS Earp III LM Graves JP Ting 2002 Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition Clin Cancer Res 8 7 2091 2099 1:CAS:528:DC%2BD38XmtVWitb8%3D 12114408 (Pubitemid 34753578)
39. HM McDaid SB Horwitz 2001 Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines Mol Pharmacol 60 2 290 301 1:CAS:528: DC%2BD3MXlsFansbg%3D 11455016 (Pubitemid 32678294)
40. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121-128
41. RS Herbst D Prager R Hermann, et al. 2005 TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 25 5892 5899 1:CAS:528:DC%2BD2MXhtVKgtbzN 10.1200/JCO.2005.02.840 16043829
42. U Gatzemeier A Pluzanska A Szczesna, et al. 2007 Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 12 1545 1552 1:CAS:528:DC%2BD2sXlsVynur4%3D 10.1200/JCO.2005.05.1474 17442998 (Pubitemid 46733081)
43. D Gandara S Narayan PN Lara Jr, et al. 2005 Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer Clin Cancer Res 11 13 Pt 2 5057s 5062s 1:CAS:528: DC%2BD2MXlvVGgtLo%3D 10.1158/1078-0432.CCR-05-9012 16000614
44. DR Gandara PH Gumerlock 2005 Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol 23 25 5856 5858 10.1200/JCO.2005.05.030 16043825
45. AM Davies C Ho PN Lara Jr P Mack PH Gumerlock DR Gandara 2006 Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer Clin Lung Cancer 7 6 385 388 1:CAS:528:DC%2BD28XmsFyqt7Y%3D 10.3816/CLC.2006.n.021 16800963 (Pubitemid 44043547)
46. Gumerlock PH, Pryde BJ, Kimura T (2003) Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol (22:abstr 2661)
47. E Giovannetti C Lemos C Tekle, et al. 2008 Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells Mol Pharmacol 73 4 1290 1300 1:CAS:528:DC%2BD1cXjvFels7k%3D 10.1124/mol.107.042382 18187583 (Pubitemid 351439211)
48. MP Morelli T Cascone T Troiani, et al. 2005 Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors Ann Oncol 16 Suppl 4 iv61 iv68 10.1093/annonc/mdi910 15923432 (Pubitemid 43084948)
49. T Li YH Ling ID Goldman R Perez-Soler 2007 Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells Clin Cancer Res 13 11 3413 3422 1:CAS:528:DC%2BD2sXmtVais74%3D 10.1158/1078-0432.CCR-06-2923 17545550 (Pubitemid 46944930)
50. TS Mok YL Wu CJ Yu, et al. 2009 Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer J Clin Oncol 27 30 5080 5087 1:CAS:528:DC%2BD1MXhsVCrsrrI 10.1200/JCO.2008.21.5541 19738125